

Set Name Query

side by side

Hit Count Set Name

result set

DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L11 (arthritis)and (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) same (c5 or c5a or c5b)same (antibod\$) and complement

6 L11*DB=USPT; PLUR=YES; OP=ADJ*L10 L9 and complement201 L10

L9 (arthritis)and (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) same (c5 or c5a or c5b)same (antibod\$)

206 L9L8 L6 and complement same arthritis167 L8L7 L6 and complement242 L7

L6 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)

250 L6*DB=USPT,PGPB; PLUR=YES; OP=ADJ*

L5 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$)same (c5 or c5a or c5b)same (antibod\$)

16 L5

L4 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)

10 L4

L3 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)

298 L3L2 5853722.pn.1 L2L1 6074642.pn.1 L1

END OF SEARCH HISTORY

Set Name Query

side by side

Hit Count Set Name

result set

DB=JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

L11 (arthritis)and (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) same (c5 or c5a or c5b)same (antibod\$) and complement

6 L11*DB=USPT; PLUR=YES; OP=ADJ*L10 L9 and complement201 L10

L9 (arthritis)and (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) same (c5 or c5a or c5b)same (antibod\$)

206 L9L8 L6 and complement same arthritis167 L8L7 L6 and complement242 L7

L6 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)

250 L6*DB=USPT,PGPB; PLUR=YES; OP=ADJ*

L5 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$)same (c5 or c5a or c5b)same (antibod\$)

16 L5

L4 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)

10 L4

L3 (arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)

298 L3L2 5853722.pn.1 L2L1 6074642.pn.1 L1

END OF SEARCH HISTORY

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT,PGPB; PLUR=YES; OP=ADJ

<u>L5</u>	(arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$)same (c5 or c5a or c5b)same (antibod\$)	16	<u>L5</u>
<u>L4</u>	(arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)	10	<u>L4</u>
<u>L3</u>	(arthritis) same (treat\$ or therap\$ or prevent\$ or block\$ or inhibit\$ or suppress\$ or anatgoni\$) and (c5 or c5a or c5b)same (antibod\$)	298	<u>L3</u>
<u>L2</u>	5853722.pn.	1	<u>L2</u>
<u>L1</u>	6074642.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
ARTHRITIS	30607
ARTHRITI	1
C5	28784
C5S	16
C5A	1248
C5AS	1
C5B	340
C5BS	0
TREAT\$	0
TREAT	144483
TREATA	1
((ARTHRITIS) SAME (TREAT\$ OR THERAP\$ OR PREVENT\$ OR BLOCK\$ OR INHIBIT\$ OR SUPPRESS\$ OR ANATGONI\$)SAME (C5 OR C5A OR C5B)SAME (ANTIBOD\$)).USPT,PGPB.	16

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Search:

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Friday, August 01, 2003 [Printable Copy](#) [Create Case](#)

WEST

Generate Collection

Print

L5: Entry 10 of 16

File: USPT

Sep 21, 1999

DOCUMENT-IDENTIFIER: US 5955441 A

TITLE: Genetic inhibition of complement mediated inflammatory response

Detailed Description Text (71):

Treatment of patients with immune disorders and diseases such as immunovascu-
litis, rheumatoid arthritis, scleroderma, disseminated intravascular coagulation, lupus,
paroxysmal nocturnal hemoglobinuria, thrombotic thrombolytic purpura, vascular
occlusion, reocclusion after surgery, coronary thrombosis, and myocardial infarction,
is accomplished by administering an effective amount of a composition containing a
C5b-9 inactivator as defined above such that procoagulant processes are suppressed. In
the case of transfused blood cells, progenitor hematopoietic stem cells derived from
or contained in bone marrow used for transplantation, or transplanted organs or
tissue, the purified membrane inhibitor of C5b-9, or the functionally equivalent
polypeptide or antibody, is first coated on the cell surface or the gene introduced
into the precursor cells before transplantation or transfusion into the recipient. The
precursor cells could be derived from the same species of origin as the recipient or
from transgenic animals of a different species wherein the gene for CD59 for the
recipient species is introduced into an embryo using techniques known to those skilled
in the art such as microinjection. The amount of composition that must be administered
to a patient in need of such treatment will vary depending on the particular disorder
or disease and the severity of affliction. Treatment dosages will also vary with the
individual patient depending upon response to treatment, genetic variability, and
effect of co-administered drugs. In general, however, the compositions disclosed
herein are administered intravenously at a dosage of approximately nanograms of
inhibitory protein or peptide per milliliter, or gene expression used to effect
surface expression of at least 1.times.10.sup.3 molecules/cell or 1 molecule
CD59/.mu.m.sup.2. Treatment can take the form of a single administration of the
composition or can be administered periodically or continuously over an extended
period of time, as required. For treatment of immune disorder or disease, the C5b-9
inactivator is administered intravenously in a pharmaceutically acceptable carrier
such as saline or a physiologically acceptable buffer. In some cases, it may be
advantageous to administer CD59 in combination with genetically engineered cells to
maximize effectiveness.

WEST☐ **Generate Collection** **Print**

L5: Entry 11 of 16

File: USPT

Jun 9, 1998

DOCUMENT-IDENTIFIER: US 5763156 A

**** See image for Certificate of Correction ****

TITLE: Inhibition of complement mediated inflammatory response

Detailed Description Text (2):

37 kDa platelet and endothelial plasma membrane inhibitors of the C5b-9 complex which normally serve to attenuate the procoagulant responses of blood platelets and endothelium exposed to activated complement proteins have been discovered by cross-reaction with a monospecific antibody (.alpha.-P18) raised against an 18 kDa erythrocyte membrane inhibitor of C5b-9 which was identified by Sugita, et al., J. Biochem. (Japan), 104:633-637, (1988). The existence of these proteins and the studies detailed below indicate that a deletion or inactivation of these cell surface components would increase the risk of vascular thrombosis and lead to a decreased storage time for platelets and platelet rich plasma (PRP), and perfused organs and transplanted tissue. Accordingly, the survival and hemostatic efficacy of platelets, and the survival of organs and tissue for transplant, which are collected and stored in vitro, can be increased by addition of the C5b-9 inhibitor to the storage buffer or perfusate. Autoimmune disorders and other disease states that involve C5b-9 mediated platelet activation, including lupus, rheumatoid arthritis, and other types of immuno-vasculitis, can also be treated by the intravascular administration an effective amount of the inhibitor to suppress C5b-9 activity, or a composition containing a polypeptide C5b-9 inhibitor to a patient requiring such treatment. Similar uses of the inhibitor may be applicable for cell culture in human blood derived culture media.

Detailed Description Text (68):

Treatment of patients with immune disorders and diseases such as immunovascularitis, rheumatoid arthritis, scleroderma, disseminated intravascular coagulation, lupus, paroxysmal nocturnal hemoglobinuria, thrombotic thrombolytic purpura, vascular occlusion, reocclusion after surgery, coronary thrombosis, and myocardial infarction, is accomplished by administering an effective amount of a composition containing a C5b-9 inactivator as defined above such that procoagulant processes are suppressed. In the case of transfused blood cells or transplanted organs or tissue, the purified membrane inhibitor of C5b-9, or the functionally equivalent polypeptide or antibody, is first coated on the cell surface before transplantation or transfusion into the recipient. The amount of composition that must be administered to a patient in need of such treatment will vary depending on the particular disorder or disease and the severity of affliction. Treatment dosages will also vary with the individual patient depending upon response to treatment, genetic variability, and effect of co-administered drugs. In general, however, the compositions disclosed herein are administered intravenously at a dosage of approximately nanograms of inhibitory protein or peptide per milliliter. Treatment can take the form of a single administration of the composition or can be administered periodically or continuously over an extended period of time, as required.

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 11 through 16 of 16 returned.**☐ 11. Document ID: US 5763156 A

L5: Entry 11 of 16

File: USPT

Jun 9, 1998

US-PAT-NO: 5763156

DOCUMENT-IDENTIFIER: US 5763156 A

**** See image for Certificate of Correction ****

TITLE: Inhibition of complement mediated inflammatory response

DATE-ISSUED: June 9, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Oklahoma City	OK		
Wiedmer; Therese	Oklahoma City	OK		

US-CL-CURRENT: 435/4; 435/2, 435/29, 435/325, 435/366, 435/372, 435/374, 435/7.1,
435/7.2, 435/7.21, 436/821, 604/7

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------	-----------------------

☐ 12. Document ID: US 5660825 A

L5: Entry 12 of 16

File: USPT

Aug 26, 1997

US-PAT-NO: 5660825

DOCUMENT-IDENTIFIER: US 5660825 A

TITLE: Method of inhibition of complement mediated inflammatory response

DATE-ISSUED: August 26, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Oklahoma City	OK		
Wiedmer; Therese	Oklahoma City	OK		

US-CL-CURRENT: 424/130.1; 424/131.1, 424/141.1, 424/158.1, 424/810, 514/12, 514/2,
530/387.2, 530/388.25

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KIMC	Draw Desc	Image
----------------------	-----------------------	--------------------------	-----------------------	------------------------	--------------------------------	----------------------	---------------------------	---------------------------	-----------------------------	------------------------	----------------------	---------------------------	-----------------------

☒ 13. Document ID: US 5635178 A

L5: Entry 13 of 16

File: USPT

Jun 3, 1997

US-PAT-NO: 5635178

DOCUMENT-IDENTIFIER: US 5635178 A

TITLE: Inhibition of complement mediated inflammatory response using monoclonal antibodies specific for a component forming the C56-9 complex which inhibit the platelet or endothelial cell activating function of the C56-9 complex

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Oklahoma City	OK		
Wiedmer; Therese	Oklahoma City	OK		

US-CL-CURRENT: 424/145.1; 530/388.25

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 14. Document ID: US 5573940 A

L5: Entry 14 of 16

File: USPT

Nov 12, 1996

US-PAT-NO: 5573940

DOCUMENT-IDENTIFIER: US 5573940 A

TITLE: Cells expressing high levels of CD59

DATE-ISSUED: November 12, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Mequon	WI		
Bothwell; Alfred L. M.	Guilford	CT		

US-CL-CURRENT: 435/362; 424/93.21, 435/69.1

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 15. Document ID: US 5550108 A

L5: Entry 15 of 16

File: USPT

Aug 27, 1996

US-PAT-NO: 5550108

DOCUMENT-IDENTIFIER: US 5550108 A

TITLE: Inhibition of complement mediated inflammatory response

DATE-ISSUED: August 27, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Oklahoma City	OK		
Wiedmer; Therese	Oklahoma City	OK		

US-CL-CURRENT: 514/21; 514/12, 514/2, 514/8, 530/350, 530/380, 530/830

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

☐ 16. Document ID: US 5135916 A

L5: Entry 16 of 16

File: USPT

Aug 4, 1992

US-PAT-NO: 5135916

DOCUMENT-IDENTIFIER: US 5135916 A

TITLE: Inhibition of complement mediated inflammatory response

DATE-ISSUED: August 4, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sims; Peter J.	Oklahoma City	OK		
Wiedmer; Therese	Oklahoma City	OK		

US-CL-CURRENT: 514/21; 514/12, 514/2, 514/8, 530/350, 530/380, 530/830

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------

KWIC	Draw Desc	Image
------	-----------	-------

[Generate Collection](#)[Print](#)

Term	Documents
ARTHRITIS	30607
ARTHRITI	1
C5	28784
C5S	16
C5A	1248
C5AS	1
C5B	340
C5BS.	0
TREAT\$	0
TREAT	144483
TREATA	1
((ARTHRITIS) SAME (TREAT\$ OR THERAP\$ OR PREVENT\$ OR BLOCK\$ OR INHIBIT\$ OR SUPPRESS\$ OR ANATGONIS)SAME (C5 OR C5A OR C5B)SAME (ANTIBOD\$)).USPT,PGPB.	16

[There are more results than shown above. Click here to view the entire set.](#)**Display Format:**

-

[Change Format](#)[Previous Page](#)[Next Page](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
ARTHRITIS	20557
ARTHRITI	3
C5	10139
C5S	2
C5A	125
C5AS	0
C5B	27
C5BS	0
COMPLEMENT	13057
COMPLEMENTS	2819
TREATS	0
((ARTHRITIS)AND (TREATS OR THERAP\$ OR PREVENTS OR BLOCK\$ OR INHIBIT\$ OR SUPPRESS\$ OR ANATGONIS) SAME (C5 OR C5A OR C5B)SAME (ANTIBOD\$) AND COMPLEMENT).JPAB,EPAB,DWPI.	6

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Search:

L11

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Friday, August 01, 2003 [Printable Copy](#) [Create Case](#)

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
ARTHRITIS	20557
ARTHRITI	3
C5	10139
C5S	2
C5A	125
C5AS	0
C5B	27
C5BS	0
COMPLEMENT	13057
COMPLEMENTS	2819
TREATS	0
((ARTHRITIS)AND (TREAT\$ OR THERAP\$ OR PREVENT\$ OR BLOCK\$ OR INHIBIT\$ OR SUPPRESS\$ OR ANATGONIS) SAME (C5 OR C5A OR C5B)SAME (ANTIBOD\$) AND COMPLEMENT).JPAB,EPAB,DWPI.	6

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	
IBM Technical Disclosure Bulletins	▼

Search:

L11

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Friday, August 01, 2003 [Printable Copy](#) [Create Case](#)